Pharma News India Weekly: Historic Semaglutide Patent Expiry Triggers Price War & Industry Shifts (March 15-21, 2026)

Published • March 21, 2026

The week of March 15-21, 2026, will be remembered as a watershed moment for the Indian pharmaceutical industry. The long-awaited patent expiry of Novo Nordisk's blockbuster drug semaglutide on March 20 unleashed a flood of generic launches, with prices crashing by up to 90%. From Natco's groundbreaking ₹1,290 vial to strategic partnerships between Zydus, Lupin, and Torrent, the GLP-1 market transformed overnight. Meanwhile, supply chain disruptions from the West Asia conflict continued to squeeze manufacturers, and traditional chemists announced a nationwide strike against online pharmacies. Here's your complete weekly roundup.

Week at a Glance: Key Takeaways

EventImpactSemaglutide Patent Expires (March 20)50+ generic brands launched; prices drop 70-90%Natco Launches at ₹1,290First generic semaglutide vial at 90% cheaper than innovatorZydus-Lupin-Torrent PartnershipsCo-marketing deals to expand reach of semaglutide genericsAIOCD Announces Nationwide Bandh (May 11)Protest against e-pharmacies and doorstep deliveryWest Asia Crisis Hits Pharma200-300% input cost surge; paracetamol API up 80% in 15 daysIndia-EU FTA Implementation€30 billion annual export gains projectedBIRAC Reports Bioeconomy GrowthIndia's bioeconomy reaches $195 billion, up 18%

Historic Moment: Semaglutide Patent Expiry Reshapes Indian Pharma

Date: March 20, 2026

The patent on semaglutide—the active ingredient in Novo Nordisk's blockbuster diabetes and weight-loss drugs Ozempic and Wegovy—expired on March 20, triggering the largest generic drug launch event in recent Indian pharmaceutical history.

The Price Revolution

Natco Pharma Fires the First Shot:

Hyderabad-based Natco Pharma launched its generic semaglutide injection at a starting price of ₹1,290 per month for multi-dose vials—a staggering 90% reduction from Novo Nordisk's innovator pricing. The company announced three vial strengths:

  • 2mg/1.5ml: ₹1,290 per month
  • 4mg/3ml: ₹1,290 per month
  • 8mg/3ml: ₹1,750 per month

Natco will also launch pen devices in April, priced between ₹4,000 and ₹4,500 per month.

Eris Lifesciences Joins the Race:

Eris, which partnered with Natco, launched its generic semaglutide under the brand "Sundae" at identical price points. The company plans to introduce pen devices in April as well.

Competitive Landscape:

At least seven domestic drugmakers launched generic semaglutide on Day 1, including:

  • Sun Pharmaceutical Industries (Noveltreat, Sematrity)
  • Dr. Reddy's Laboratories
  • Zydus Lifesciences (Semaglyn, Mashema, Alterme)
  • Alkem Laboratories
  • Mankind Pharma
  • Lupin (co-marketing with Zydus)
  • Torrent Pharmaceuticals (Sembolic, co-marketing with Zydus)

Price Comparison:

ProductMonthly PriceDiscount vs InnovatorNovo Nordisk Wegovy₹10,850-16,400—Novo Nordisk Ozempic₹8,800-11,175—Natco Vial (2mg)₹1,29090% cheaperNatco Pen Device₹4,000-4,50070% cheaperEris Sundae Vial₹1,29090% cheaper

Strategic Partnerships Reshape Market

Zydus-Lupin Collaboration:

Zydus Lifesciences signed a licensing and supply agreement with Lupin to co-market semaglutide injection in India. Under the semi-exclusive arrangement:

  • Lupin will market under brand names Semanext and Livarise
  • Zydus will market under Semaglyn, Mashema, and Alterme
  • The therapy uses an innovative reusable pen device designed for multiple dose strengths

Zydus-Torrent Partnership:

Zydus also partnered with Torrent Pharmaceuticals, granting Torrent semi-exclusive rights to co-market semaglutide under the brand "Sembolic." Torrent will leverage its strong presence in chronic therapies and extensive field force across India.

Emcure's Innovator Edge:

Emcure Pharmaceuticals, which partnered with Novo Nordisk to market semaglutide as Poviztra, is banking on the "innovator edge." The drugmaker emphasizes that Novo's semaglutide is a biological molecule—97% similar to natural body chemicals—which may be preferred by specialists for its efficacy, tolerability, and side-effect profile.

Novo Nordisk's Strategy:

Novo Nordisk India MD Vikrant Shrotriya said the company will closely track generic competition rather than entering a price war. "When we were carving out the market position one year back, we had no clue that 40 players will come... now, as we are coming closer, the entire telescope is converting into a microscope," he stated.

Market Outlook

The GLP-1 market in India currently stands at approximately ₹1,500 crore, with Eli Lilly's Mounjaro (tirzepatide) commanding 85% share. Analysts project:

  • Two-fold jump in GLP-1 unit sales over the next three months
  • Market to grow fivefold to ₹5,000-6,000 crore by 2030
  • Prices expected to decline further by 10-30% in FY28 due to intense competition

Doctors Warn Against Misuse of Weight-Loss Drugs

Date: March 15-21, 2026

As cheaper generics hit the market, medical professionals across India have raised urgent concerns about potential misuse and unsupervised consumption.

Cosmetic Weight-Loss Demand Surges:

Doctors report a sharp rise in inquiries from otherwise healthy individuals seeking weight-loss drugs for cosmetic purposes. Mumbai-based diabetologist Dr. Rajiv Kovil noted, "There are clear clinical criteria for prescribing this drug, and it is not meant for cosmetic weight loss."

Eligibility Criteria:

Patients without diabetes must meet specific body mass index thresholds and have obesity-related conditions to qualify for therapy.

Potential Risks:

Experts warn of serious side effects including:

  • Nausea, vomiting, gastrointestinal issues
  • Pancreatitis (in rare cases)
  • Thyroid cancer risk
  • Gallbladder complications

Dr. Aparna Govil Bhasker, a Mumbai-based bariatric surgeon, cautioned: "This is not something you pick up after seeing it on Instagram or hearing a celebrity talk about it. It has specific indications and potential side effects, some of them serious."

Regulatory Response:

The Central Drugs Standard Control Organisation has already banned surrogate advertising for GLP-1 drugs and classified them as Schedule H prescription drugs requiring mandatory medical supervision.

AIOCD Announces Nationwide Pharmacy Bandh on May 11

Date: March 21, 2026

The All India Organisation of Chemists and Druggists (AIOCD) has formally announced a nationwide strike—a "National Pharmacy Bandh"—scheduled for May 11, 2026.

Key Demands:

  1. Withdrawal of government notifications GSR 220(E) and GSR 817(E), which AIOCD argues create loopholes allowing e-pharmacies to bypass the Drugs and Cosmetics Act
  2. Regulation of online pharmacies operating in a regulatory vacuum
  3. Opposition to doorstep delivery systems for medicines proposed by government agencies
  4. Standardized pricing environment to counter deep discounts offered by large chain pharmacies and online players

Scale of Protest:

The decision was finalized during the national executive committee meeting in Udaipur on March 15, with over 250 members participating. The date was moved from April 15 to May 11 to avoid clashing with Assembly elections in five states.

Impact:

The bandh is expected to affect more than 12.40 lakh brick-and-mortar chemists across India. Emergency pharmacies within hospitals will remain operational to ensure patient safety.

AIOCD Statement:

General Secretary Rajiv Singhal expressed "deep frustration over the government's lackadaisical attitude toward regulating online pharmacies," arguing these platforms "encourage self-medication and contribute to the global threat of antimicrobial resistance."

West Asia Crisis: Pharma Units Face 200-300% Input Cost Surge

Date: March 15-21, 2026

The ongoing West Asia conflict continued to severely impact pharmaceutical manufacturing, with input costs rising dramatically across the sector.

Alarming Price Increases:

The Himachal Drug Manufacturers Association (HDMA), representing over 500 pharma units, reported unprecedented price hikes:

InputPrice IncreaseParacetamol API80% (₹250 to ₹450/kg in 15 days)Glycerin64%Propylene Glycol25-30%Packaging Materials200-300% overall

Manufacturing Disruptions:

  • Boiler operations impacted due to propane/LPG shortage
  • Approximately 200 manufacturers may halt production within 7-10 days
  • Punjab-based pharmaceutical units report 30% rise in manufacturing costs
  • Exports to West Asia and North Africa completely stalled

Industry Response:

HDMA has urged the government to impose "emergency price ceilings" and form a "crisis task force." The association also called for strict action against black marketeers creating artificial scarcity.

Government Relief:

The government announced the RELIEF (Resilience & Logistics Intervention for Export Facilitation) package with a ₹497 crore outlay under the Export Promotion Mission, providing enhanced insurance coverage for exporters affected by the crisis.

Corporate Developments: Major Deals & Expansions

Mankind Pharma Acquires Roche's Rivotril

Mankind Pharma acquired the Rivotril brand from Roche for the Indian market, securing exclusive rights for domestic manufacture, marketing, and distribution. The acquisition strengthens Mankind's neurological products portfolio.

Eisai Launches Global Capability Centre in Visakhapatnam

Japanese pharma major Eisai Co. Ltd established its Global Capability Centre (EGCC) in Visakhapatnam to standardize global IT infrastructure operations and digital transformation. The centre will gradually expand its scope to include cybersecurity, data analytics, and operational applications.

Lupin Eyes US Growth with Complex Generics, Biosimilars

Lupin is positioning itself for the next phase of global growth focused on complex generics, biosimilars, and innovation in the US market. The company plans to launch five biosimilars globally over the next five years, targeting major markets including the US, Europe, and Japan.

Strides Pharma Acquires Sandoz Generics Portfolio

Strides Pharma International AG signed a $12 million deal to acquire and in-license a portfolio of branded generic products across sub-Saharan Africa from Sandoz AG. The transaction spans four key markets: West Africa (10 countries), Ghana, Nigeria, and Kenya.

Zydus Drug Gets China Approval

Zydus Lifesciences received marketing approval from China's National Medical Products Administration for Desidustat tablets, used for treating anaemia in Chronic Kidney Disease patients. China has an estimated 120 million CKD patients.

Bharat Biotech Targets Antimicrobial Resistance

Hyderabad-based Bharat Biotech is developing a novel vaccine strategy to tackle antimicrobial resistance (AMR), focusing on vaccines that could be administered before surgeries to prevent hospital-acquired infections. The company also has four novel vaccines entering phase three efficacy trials.

Regulatory Developments

CDSCO Issues Dossier-Based Drug Licensing Guidelines

The Central Drugs Standard Control Organisation issued comprehensive guidelines for dossier-based drug manufacturing licence issuance and renewal, aiming to ensure uniform product licensing and quality standards across India.

HC Seeks Government Response on Ozempic Misuse

The Delhi High Court sought responses from the government and CDSCO on a contempt petition alleging non-compliance with directions to assess misuse of diabetes drugs like Ozempic for weight loss.

HC Slams Patents Body for Novartis Delay

The Delhi High Court pulled up the Controller General of Patents for failing to decide on Novartis AG's patent application for breast cancer drug Ribociclib since 2011, calling it an "unfortunate and sorry state of affairs."

India-EU Trade Pact: €30 Billion Export Gains Projected

European Parliament Member Anna Sturgkh projected that the India-EU free trade agreement will generate €30 billion (₹3.2 trillion) in combined annual export gains. "From Austrian machinery to Indian pharmaceuticals, businesses on both sides will find new opportunities, creating jobs and driving innovation," she stated in an article published in The Europe India Journal.

The agreement is expected to be implemented by November 2026.

India's Bioeconomy Reaches $195 Billion

The India Bioeconomy Report 2026, published by BIRAC, revealed that India's bioeconomy valuation surged from $166 billion in 2024 to $195 billion in 2025—an 18% growth, the highest in recent years.

Key Growth Drivers:

  • 20% ethanol blending in petrol
  • GLP-1 class of drug consumption
  • New Global Capability Centres employing over 300,000 Indian professionals
  • Biosolutions using enzymes and microbes in industrial sectors

Future Targets:

BIRAC aims to grow India's bioeconomy to $300 billion by 2030 and $1 trillion by 2047.

International News (PharmaTimes, March 15-21, 2026)

Clinical Trials & Approvals:

  • Arvinas reported strong phase 1 results for ARV-102 in Parkinson's disease with >50% LRRK2 reduction
  • Samsung Bioepis signed partnership with Sandoz for next-generation biosimilars covering up to five candidates
  • Atrogi began dosing first subjects in human trial of ATR-258 for muscle-sparing weight loss
  • R1 Therapeutics launched with $77.5m to advance hyperphosphatemia treatment
  • Elevara began phase 2b trial of ELV001 in rheumatoid arthritis
  • Lebrikizumab showed strong results for children with atopic dermatitis in phase 3 trial
  • Lundbeck completed patient randomisation early in global MSA trial

Regulatory Approvals:

  • MHRA approved deuruxolitinib for severe alopecia areata
  • NHS to offer fezolinetant for menopause-related hot flushes

Trade & Export Updates

Exports Contract in February

India's merchandise exports contracted 0.8% in February to $36.61 billion—the first decline in four months. Commerce Secretary Rajesh Agrawal cautioned that March will be "challenging" due to West Asia logistics disruptions.

CBIC Eases Back-to-Town Clearance

The Central Board of Indirect Taxes and Customs clarified that containers loaded at one Indian port but offloaded at another on return can be cleared under the back-to-town procedure, resolving confusion that had emerged over jurisdictional issues.

Concor Slashes Storage Charges

Container Corporation of India announced a 30-day "dies non" period for factory-stuffed export-laden containers, along with 5% rail freight discount and 30% discount on reefer plug-in charges.

Zydus-Lupin Semaglutide Deal: A Closer Look

The partnership between Zydus and Lupin represents a significant strategic move in the GLP-1 market. Under the agreement:

  • Zydus will manufacture and supply semaglutide injection (15mg/3ml) with an innovative reusable pen device
  • Lupin receives semi-exclusive rights to co-market the product in India under brand names Semanext and Livarise
  • Financial terms: Upfront licensing fees plus milestone payments on achieving pre-defined targets

Dr. Sharvil Patel, MD of Zydus: "The innovative pen device we are offering is designed to make therapy simpler and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine."

Nilesh Gupta, MD of Lupin: "As GLP-1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs."

Key Data Points Summary

MetricValueGLP-1 market size (Feb 2026)₹1,500 croreNatco semaglutide vial price₹1,290/month (90% cheaper)Generic brands launched50+Companies launching generics40+Expected market by 2030₹5,000-6,000 croreParacetamol API increase80% in 15 daysIndia's bioeconomy (2025)$195 billion (▲18%)India-EU FTA export gains€30 billion/yearAIOCD bandh dateMay 11, 2026

Frequently Asked Questions

What are the top pharmaceutical trends for 2026?

Key trends include: 1) GLP-1 market explosion with 50+ generic entrants post-patent expiry, 2) Biosimilars growth with companies like Lupin planning five launches globally, 3) Geopolitical supply chain resilience becoming strategic priority, 4) Digital transformation in manufacturing, 5) Trade expansion through FTAs, and 6) Regulatory crackdown on e-pharmacies.

What are the latest pharma news updates this week?

The historic patent expiry of semaglutide on March 20 triggered generic launches at 90% lower prices. Natco launched at ₹1,290/month, Zydus partnered with Lupin and Torrent for co-marketing, AIOCD announced a nationwide strike for May 11 against e-pharmacies, and the West Asia crisis caused 200-300% input cost surges.

What is happening in the pharmaceutical industry this week?

The industry is witnessing a seismic shift with the patent expiry of the blockbuster weight-loss drug semaglutide. Over 40 companies launched generic versions at prices as low as ₹1,290 per month. Meanwhile, manufacturers are grappling with severe input cost inflation due to the West Asia conflict, and traditional chemists are organizing a nationwide protest against online pharmacies.

Where can I find all weekly pharma industry news?

For comprehensive weekly updates on the Indian pharmaceutical industry, including market trends, policy changes, and corporate developments, visit GreenCrossIndia.com/blog.

What is Zydus's latest news this week?

Zydus Lifesciences signed licensing and supply agreements with both Lupin and Torrent Pharmaceuticals to co-market generic semaglutide injection in India. The company also received marketing approval from China's NMPA for its Desidustat tablets for treating anaemia in Chronic Kidney Disease patients.

How is the West Asia war affecting Indian pharma?

The conflict has triggered unprecedented price hikes: paracetamol API up 80% in 15 days, glycerin up 64%, packaging materials up 200-300%. Boiler operations are impacted due to LPG shortage, with 200 manufacturers facing potential shutdown. The government has announced a ₹497 crore RELIEF package for affected exporters.

Disclaimer and References

This article is prepared for informational and educational purposes only and summarizes pharmaceutical industry developments during 15–21 March 2026. The information has been compiled from publicly available reports and industry news sources including Economic Times, Business Line, Financial Express, Indian Express, Hindustan Times, Mint, Pharmarack market data, and international pharmaceutical news platforms. Readers are advised to verify official announcements from companies, regulators, and government authorities before making business, medical, or financial decisions.

APPLY FOR PCD PHARMA FRANCHISE